文献速递其他结缔组织病

一项研究mPGES-1抑制剂vipoglanstat治疗系统性硬化症相关雷诺现象的疗效与安全性的2期试验

A phase 2 trial investigating the efficacy and safety of the mPGES-1 inhibitor vipoglanstat in systemic sclerosis-related Raynaud's.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

这项双盲、安慰剂对照2期试验将69例系统性硬化症(SSc)且筛选前一周内至少7次雷诺现象(RP)发作的患者随机分配至vipoglanstat 120 mg组(n=33)或安慰剂组(n=36)治疗4周。主要终点每周RP发作次数在vipoglanstat组平均减少3.4次(95%CI -5.8; -1.0),安慰剂组减少4.2次(95%CI -6.5; -2.0),组间P=0.628。vipoglanstat完全抑制mPGES-1,但结论为对SSc相关RP无效。

要点

  • vipoglanstat组每周RP发作减少3.4次(95%CI -5.8; -1.0),安慰剂组减少4.2次(95%CI -6.5; -2.0),P=0.628。
  • 所有患者报告结局均改善,但组间无差异。
  • vipoglanstat安全且耐受良好,完全抑制mPGES-1,使尿PGE2降低57%、前列环素代谢物增加50%。

核心结论

  • vipoglanstat在达到完全抑制mPGES-1的剂量下安全且耐受良好,但对SSc相关RP无效;进一步的开发与评估将转向mPGES-1发挥致病作用的其他疾病。

研究设计与样本

  • 双盲、安慰剂对照2期试验,纳入69例SSc且基线访视前最后筛选周内至少7次RP发作的患者,随机接受vipoglanstat 120 mg(n=33)或安慰剂(n=36)治疗4周。
  • 每日电子日记记录RP发作(持续时间与疼痛)及雷诺状况评分,主要终点为每周RP发作次数的变化;基线与治疗结束时进行冷激发评估。

主要发现

  • 每周RP发作次数基线:vipoglanstat组14.4次(标准差6.7),安慰剂组18.2次(标准差12.6);分别减少3.4次(95%CI -5.8; -1.0)与4.2次(95%CI -6.5; -2.0),P=0.628。
  • 所有患者报告结局均改善,组间无差异;冷激发后外周血流恢复的平均变化组间无差异。
  • vipoglanstat完全抑制mPGES-1,使尿PGE2降低57%、前列环素代谢物增加50%;vipoglanstat安全且耐受良好。

关键数值与推荐

  • 探索性终点包括患者与医生整体变化印象、硬皮病相关雷诺现象评估问卷、mPGES-1活性及尿花生四烯酸代谢物排泄。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Our objective was to test the hypothesis, in a double-blind, placebo-controlled study that vipoglanstat, an inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1), which decreases prostaglandin E2 (PGE2) and increases prostacyclin biosynthesis, improves RP. METHODS: Patients with SSc and ≥7 RP attacks during the last screening week prior to a baseline visit were randomized to 4 weeks treatment with vipoglanstat 120 mg or placebo. A daily electronic diary captured RP attacks (duration and pain) and Raynaud's Condition Score, with change in RP attacks/week as the primary end point. Cold challenge assessments were performed at baseline and end of treatment. Exploratory end points included patients' and physicians' global impression of change, Assessment of Scleroderma-associated Raynaud's Phenomenon questionnaire, mPGES-1 activity, and urinary excretion of arachidonic acid metabolites. RESULTS: Sixty-nine subjects received vipoglanstat (n = 33) or placebo (n = 36). The mean weekly number of RP attacks [baseline; vipoglanstat 14.4 (S.D. 6.7), placebo 18.2 (12.6)] decreased by 3.4 (95% CI -5.8; -1.0) and 4.2 (-6.5; -2.0) attacks per week (P = 0.628), respectively. All patient-reported outcomes improved, with no difference between the groups. The mean change in recovery of peripheral blood flow after the cold challenge did not differ between the study groups. Vipoglanstat fully inhibited mPGES-1, resulting in 57% reduction of PGE2 and 50% increase of prostacyclin metabolites in the urine. Vipoglanstat was safe and well tolerated. CONCLUSION: Although vipoglanstat was safe, and well tolerated in a dose achieving full inhibition of mPGES-1, it was ineffective in SSc-related RP. Further development and evaluation of vipoglanstat will therefore be in other diseases where mPGES-1 plays a pathogenetic role. TRIAL REGISTRATION: ClinicalTrials.gov, https://www.clinicaltrials.gov, NCT0474420.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Tornling G, Edenius C, Pauling JD, et al. A phase 2 trial investigating the efficacy and safety of the mPGES-1 inhibitor vipoglanstat in systemic sclerosis-related Raynaud's. Rheumatology (Oxford). 2025. PMID: 38291895. doi:10.1093/rheumatology/keae049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。